- Mireia Córcoles
- No Comments
- THESpanish Agency for Medicines and Health Products has compiled a ranking that evaluates the activity of the CEIms in the state and places Parc Taulí in fourth place in Spain and second in Catalonia
El Ethics and Drug Research Committee (CEIm) of Parc Taulí is the fourth committee of Spain and the second in Catalonia en number of clinical trials with evaluated drugs during 2021, according to theSpanish Agency for Medicines and Health Products (AEMPS).
Specifically, Parc Taulí has evaluated a total of 67 projects with clinical trials with drugs throughout 2021, which represents 6% of the total number of projects of this nature that have been evaluated throughout the year in the state.
In the current edition of the classification, Parc Taulí has improved a position with respect to the one published the previous year and confirms, according to Lluís Blanch, director of the Parc Taulí Research and Innovation Institute (I3PT), “the excellent growth of the CEIm of Parc Taulí and its position as a reference body in the state”.
The ranking, led by the CEIm of the Vall d'Hebron University Hospital, has positioned the 24 CEIm in the state with the most research projects carried out on evaluated humans. These 24 agencies are responsible for 90% of the ongoing evaluation activity across the state.
The functions of the CEIm
The CEIm are accredited independent bodies, in accordance with Royal Decree 1090/2015, to evaluate and issue opinions on clinical studies with medicines and clinical research with health products.
Specifically, a CEIM evaluates all research aimed at developing drugs for use in humans. Accordingly, it issues an opinion on the trial protocol, the suitability of the research team and the facilities, as well as the methodology and documents used to inform the participants in the trial. .
CEIm also monitors the clinical trial from start to finish.
Head of CommunicationAll stories by: Mireia Córcoles
Leave a Reply